Arlene Siefker-Radtke, MD
Medical Oncology · Houston, TXNPI 1700979275
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $149,788 of the $204,820 with a category attached, or 73.1%. It is spread thinly across 26 manufacturers, the largest accounting for just 14.7%. Among medical oncology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 209 payments — averaging $980.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Seagen Inc.$30K
- Janssen Global Services, LLC$27K
- Merck$25K
- Astellas Pharma Europe Ltd$21K
- Gilead$17K
- Johnson & Johnson$13K
- plus $71K from 20 others
Across 346 payments — averaging $7754.46 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$1.1M
- Eli Lilly$716K
- Merck$589K
- E.r. Squibb & Sons, L.L.C.$255K
What the payments were for
- Consulting fees$149,78873%
- Speaking & faculty fees$33,55616%
- Travel & lodging$15,2557%
- Food & beverage$6,1453%
- Education$760%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Seagen Inc. | 37 | $30,163 |
| Janssen Global Services, LLC | 25 | $27,245 |
| Merck | 19 | $24,975 |
| Astellas Pharma Europe Ltd | 4 | $21,057 |
| Gilead | 20 | $17,080 |
| Johnson & Johnson | 27 | $13,364 |
| EMD Serono, Inc. | 2 | $8,620 |
| Astellas Pharma US Inc | 3 | $8,464 |
| Urogen Pharma, Inc. | 1 | $8,250 |
| Genentech, Inc. | 6 | $7,433 |
| Astellas Pharma Global Development | 5 | $6,534 |
| Taiho Oncology, Inc. | 5 | $5,208 |
| AbbVie | 2 | $4,550 |
| G1 Therapeutics, Inc. | 1 | $3,480 |
| Astrazeneca UK Limited | 2 | $3,155 |
| E.r. Squibb & Sons, L.L.C. | 5 | $3,099 |
| AstraZeneca | 1 | $3,000 |
| Janssen Research & Development, LLC | 7 | $2,760 |
| Pfizer | 8 | $2,566 |
| Eli Lilly | 4 | $2,020 |
| Qiagen, LLC | 1 | $1,000 |
| Bristol Myers Squibb | 1 | $300 |
| Exelixis Inc. | 19 | $275 |
| Janssen Scientific Affairs, LLC | 1 | $127 |
| Genentech USA, Inc. | 1 | $61 |
| Sumitomo Pharma America, Inc. | 2 | $34 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$204,820 in reported general payments places this provider in the 90th percentile of 495 medical oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Houston
- Roy HerbstHouston$1.9M
- Maen AbdelrahimHouston$999K
- John HeymachHouston$726K
- Putao CenHouston$720K
- Hagop KantarjianHouston$559K
- Ricardo AlvarezHouston$553K
- Eleni EfstathiouHouston$519K
- Srdan VerstovsekHouston$464K
- Guillermo Garcia-ManeroHouston$454K
- Jason WestinHouston$407K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.